Quick Answer
IO Biotech, Inc. reported R&D Expense of $71.48 million for fiscal year 2024.
IO Biotech, Inc. R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2024 | $71.48M | +5.4% |
| 2023 | $67.83M | +44.4% |
| 2022 | $46.99M | +55.8% |
| 2021 | $30.15M | +256.2% |
| 2020 | $8.46M | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $13.74M | -31.9% | -17.5% |
| June 30, 2025 | $16.65M | +5.1% | +1.7% |
| March 31, 2025 | $16.38M | +14.4% | -18.8% |
| September 30, 2024 | $20.18M | +14.3% | +27.3% |
| June 30, 2024 | $15.85M | -4.0% | +10.7% |
| March 31, 2024 | $14.31M | +20.3% | -18.9% |
| September 30, 2023 | $17.66M | +76.2% | +7.0% |
| June 30, 2023 | $16.50M | +35.0% | +38.7% |
- IO Biotech, Inc. showed an increase of +5.4% in R&D Expense compared to the prior fiscal year.
- Over the 2020–2024 period, IO Biotech, Inc.’s r&d expense has grown by 744.6% (from $8.46 million to $71.48 million).
- The most recent figure is from IO Biotech, Inc.’s fiscal year 2024 report (Form 10-K), filed with the SEC on March 31, 2025.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: